| Literature DB >> 35060520 |
Kyunghak Choi1, Min Soo Kim2, Min Ae Keum1, Seongho Choi1, Kyu-Hyouck Kyoung1, Jihoon T Kim1, Sungjeep Kim1, Minsu Noh1.
Abstract
ABSTRACT: Research on long-term renal outcomes in patients with acute kidney injury (AKI) and trauma, especially those with traumatic brain injury (TBI), has been limited.In this study, we enrolled patients with stage 3 AKI as per the Kidney Disease Improving Global Outcomes guidelines, who initiated renal replacement therapy (RRT). These patients were divided into 2 groups depending on the presence of TBI. Comparing the baseline characteristics and management strategies of each group, we analyzed whether TBI affects the progression of kidney disease.Between January 1, 2014 and June 30, 2020, 51 patients who initiated RRT due to AKI after trauma were enrolled in this study. TBI was identified in 20 patients, and the clinical conditions were not related to TBI in the remaining 31. The study endpoint was set to determine whether the patients of each group needed RRT persistently at discharge and at the time of recent outpatient clinic. Six (30.0%) out of 20 patients with TBI and 2 (6.5%) out of 31 patients without TBI required conventional hemodialysis, as per the most recent data. No significant within-group differences were found in terms of the baseline characteristics and management strategies. In the logistic regression analysis, TBI was independently associated with disease progression to end-stage renal disease.TBI is a risk factor for end-stage renal disease in patients with trauma and stage 3 AKI who initiate RRT.Entities:
Mesh:
Year: 2022 PMID: 35060520 PMCID: PMC8772680 DOI: 10.1097/MD.0000000000028581
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.889
Staging of acute kidney injury according to the Kidney Disease Improving Global Outcomes guidelines.
| Stage | Serum creatinine | Urine output |
| 1 | 1.5–1.9 times baselineor≥0.3 mg/dL (≥26.5 μmol/L) increase | <0.5 mL/kg/h for 6–12 h |
| 2 | 2.0–2.9 times baseline | <0.5 mL/kg/h for ≥12 h |
| 3 | 3.0 times baselineorIncrease in sCr to ≥4.0 mg/dL (≥353.6 μmol/L)orInitiation of renal replacement therapy | <0.3 mL/kg/h for ≥24 horAnuria for ≥12 h |
Figure 1Study enrollment flow diagram. CKD = chronic kidney disease, HD = hemodialysis, RRT = renal replacement therapy, TBI = traumatic brain injury.
General characteristics of the patients.
| Characteristic | ||
| Age, median (range) | 55 | (18–84) |
| Male sex, | 39 | (76.5%) |
| ISS, median (range) | 25 | (4–50) |
| APACHE II, median (range) | 26 | (4–41) |
| TBI, median (range) | 20 | (39.2%) |
| HTN, | 17 | (33.3%) |
| DM, | 4 | (7.8%) |
| HL, | 2 | (3.9%) |
| CVA, | 3 | (5.9%) |
| CAD, | 4 | (7.8%) |
| Malignancy, | 3 | (5.9%) |
| Operation, | 46 | (90.2%) |
| Head and neck, | 16 | |
| Thorax, | 8 | |
| Abdominopelvic, | 29 | |
| Spine, | 2 | |
| Extremities, | 24 | |
| RRT at discharge, | 8 | (15.7%) |
| Follow-up (d), median (range) | 489 | (15–2348) |
Comparison of patient groups according to traumatic brain injury.
| Variables | No TBI ( | TBI ( | |||
| Age, median (range) | 58 | (18–84) | 54 | (18–77) | .699 |
| Male sex, | 24 | (77.4%) | 15 | (75%) | – |
| ISS, median (range) | 22 | (5–43) | 29 | (4–50) | .119 |
| APACHE II, median (range) | 27 | (5–41) | 26 | (4–35) | .595 |
| HTN, | 10 | (32.3%) | 7 | (35%) | .839 |
| DM, | 1 | (3.2%) | 3 | (15%) | .287 |
| HL, | 1 | (3.2%) | 1 | (5%) | – |
| CVA, | 1 | (3.2%) | 2 | (10%) | .553 |
| CAD, | 2 | (6.5%) | 2 | (10%) | .640 |
| Malignancy, | 1 | (3.2%) | 2 | (10%) | .553 |
| Vasopressor, | 28 | (90.3%) | 18 | (90%) | – |
| Lactate (mmol/L), median (range) | 4.80 | (1.00–14.00) | 6.05 | (0.90–15.00) | .429 |
| CRP (mg/L), median (range) | 26.19 | (4.37–46.22) | 29.235 | (5.19–43.05) | .385 |
| PCT (ng/mL), median (range) | 8.38 | (0.33–154.99) | 6 | (0.42–403.90) | .805 |
| BUN (mg/dL), median (range) | 85.6 | (25.60–183.30) | 83.9 | (23.90–159.90) | .938 |
| Cr (mg/dL), median (range) | 5 | (1.38–11.75) | 4.62 | (1.19–13.11) | .602 |
| GFR (mL/min/1.73 m2), median (range) | 12 | (1.00–57.00) | 14.5 | (4.00–53.00) | .595 |
| ICU days, median (range) | 34 | (4–131) | 37.5 | (3–253) | .582 |
| RRT at discharge, | 2 | (6.5%) | 6 | (30%) | .045 |
Logistic regression analysis of risk factors for persistent renal replacement therapy.
| Variables | Odds ratio | 95% CI | |
| Age | 1.043 | 0.970–1.121 | .253 |
| Male sex | 1.597 | 0.172–14.793 | .680 |
| ISS | 1.020 | 0.940–1.106 | .634 |
| TBI | 6.316 | 1.054–37.836 | .044 |
| HTN | 0.749 | 0.066–8.493 | .816 |
| CRP | 1.092 | 0.976–1.221 | .123 |
Comparison of patients with traumatic brain injury according to the status of persistent renal replacement therapy.
| Variables | No RRT ( | RRT ( | |||
| Age, median (range) | 53.5 | (18–76) | 64.5 | (33–77) | .173 |
| Male sex, | 11 | (78.6%) | 4 | (66.7%) | .613 |
| ISS, median (range) | 29.5 | (4–50) | 19.5 | (9–43) | .456 |
| APACHE II, median (range) | 26 | (6–35) | 24 | (4–29) | .231 |
| AIS, head, median | 3.5 | (2–5) | 4 | (3–5) | .391 |
| HTN, | 4 | (28.6%) | 3 | (50.0%) | .613 |
| DM, | 3 | (21.4%) | 0 | (0.0%) | .521 |
| HL, | 1 | (7.1%) | 0 | (0.0%) | – |
| CVA, | 2 | (14.3%) | 0 | (0.0%) | – |
| CAD, | 2 | (14.3%) | 0 | (0.0%) | – |
| Malignancy, | 0 | (0.0%) | 2 | (33.3%) | .079 |
| Operation, | 13 | (92.9%) | 5 | (83.3%) | .521 |
| Vasopressor, | 12 | (85.7%) | 6 | (100.0%) | – |
| Lactate (mmol/L), median (range) | 6.45 | (0.9–15.0) | 3.80 | (2.06–8.20) | .302 |
| CRP (mg/L), median (range) | 27.36 | (5.19–39.57) | 35.06 | (25.78–43.05) | .013 |
| PCT (ng/mL), median (range) | 6.00 | (0.42–55.80) | 7.96 | (0.89–403.90) | .888 |
| BUN (mg/dL), median (range) | 66.9 | (23.9–159.9) | 109.3 | (60.2–154.9) | .248 |
| Cr (mg/dL), median (range) | 3.62 | (1.19–8.54) | 6.33 | (4.46–13.11) | .058 |
| GFR (mL/min/1.73 m2), median (range) | 17.5 | (8–53) | 7.5 | (4–29) | .002 |
| ICU days, median (range) | 37.5 | (3–253) | 32 | (15–69) | .620 |